8-K: TELA Bio Sells Distribution Rights for Wound Care Product to MiMedx for Up to $12 Million

TELA Bio has sold the distribution rights for its NIVIS Fibrillar Collagen Pack to MiMedx for an initial payment of $5 million, with potential future payments up to $7 million based on sales performance.

Summary

• TELA Bio has completed the sale of its distribution rights for the NIVIS Fibrillar Collagen Pack to MiMedx.
• The deal includes an initial payment of $5 million to TELA Bio.
• TELA Bio is also eligible for additional payments ranging from $3 million to $7 million over the next two years, based on net sales of NIVIS.
• The total consideration for the sale could reach up to $12 million.
• NIVIS is a collagen matrix used for managing moderately to heavily exudating wounds and controlling minor bleeding.
• MiMedx is a company focused on wound care, burn, and surgical products.

Sentiment

Score: 7

Explanation: The deal is positive for TELA Bio, providing immediate cash and potential future revenue, but it also involves some risk and loss of direct control over NIVIS sales. The sentiment is moderately positive.

Positives

• TELA Bio receives an immediate cash infusion of $5 million.
• The deal provides potential for additional revenue of up to $7 million over the next two years.
• The sale allows TELA Bio to focus on its core hernia repair and reconstructive surgery products.
• MiMedx's expertise in wound care could lead to increased market penetration for NIVIS.

Negatives

• TELA Bio is giving up future revenue potential from direct sales of NIVIS.
• The additional payments are contingent on MiMedx achieving certain sales targets, which are not guaranteed.

Risks

• The additional payments are dependent on the sales performance of NIVIS by MiMedx.
• There is a risk that MiMedx may not achieve the sales targets required for TELA Bio to receive the full $7 million in additional payments.
• TELA Bio is now reliant on MiMedx for the distribution and sales of NIVIS.

Future Outlook

TELA Bio intends to focus on expanding its portfolio of hernia repair and reconstructive surgery products, including new LIQUIFIXTM hernia mesh fixation devices and new product configurations of OviTex Reinforced Tissue Matrix.

Management Comments

• Antony Koblish, President and CEO of TELA Bio, stated they are confident in MiMedx's capabilities to drive market share for NIVIS.
• TELA Bio is looking forward to expanding the use of their hernia repair and reconstructive surgery products.

Industry Context

This transaction reflects a trend in the medical device industry where companies focus on their core competencies and partner with others for distribution and sales. MiMedx's focus on wound care aligns well with the NIVIS product, potentially leading to increased market penetration.

Comparison to Industry Standards

• The sale of distribution rights is a common strategy in the medical device industry, allowing companies to monetize assets while focusing on core product development.
• Similar deals often involve upfront payments and milestone-based payments tied to sales performance.
• Companies like Integra LifeSciences and Smith & Nephew also engage in strategic partnerships and acquisitions to expand their product portfolios and market reach.

Stakeholder Impact

• Shareholders may view the deal positively due to the immediate cash and potential future revenue.
• Employees may see a shift in focus towards hernia repair and reconstructive surgery products.
• Customers may experience changes in how they access NIVIS products through MiMedx.

Next Steps

• TELA Bio will focus on expanding its hernia repair and reconstructive surgery product portfolio.
• MiMedx will begin distributing and selling NIVIS.

Key Dates

Keywords

TELA Bio, MiMedx, NIVIS, distribution rights, wound care, collagen matrix, medical technology, soft-tissue reconstruction, surgical products